

# Deals and M&A Biotech and Medtech

1st Semester 2017



503 deals worldwide



Total worth > 35 Bn\$  
Average deal value 378 M\$



36 % of deals in oncology



11% in neurology

> 1/3 of deals are licensing agreements



36% antibodies



13% cell therapy



12% protein / peptide



10% biomarker



37% of deals for biologics



22% for small molecules

## American companies are present in 9 out of 10 top deals

### Top 3 deals worldwide

- #1 **2.85 Bn\$**  
Stage : marketed  
Antibody  
Auto-immune
- #2 **2.83 Bn\$**  
Stage : preclinical  
Gastrointestinal
- #3 **2.15 Bn\$**  
Stage : preclinical  
Protein  
Pulmonary

### Top 3 deals with French biotech

- #1 **460 M\$**  
Stage : preclinical  
Antibody  
Oncology
- #2 **257 M\$**  
Oncology
- #3 **242 M\$**  
Stage : phase II  
Protein  
Auto-immune

Source: BioCentury (July 2017)

1st Semester 2017



60 M&A operations  
worldwide

47 acquisitions

13 mergers

### Main therapeutic areas of companies



23 % in oncology



8% in neurology



7% infectious diseases

Total worth > 49 Bn\$  
Average deal value 1.7 Bn\$

Stage of target company at signing



Preclinical or phase I (23%) Phase II (30%)  
Phase III or market (47%)



26% protein / peptide



21% antibodies



16% vaccine



32% for biologics



25% for small molecules

## Top 3 M&A operations Full acquisitions

- #1 **30 Bn\$**  
 bought by
- #2 **5.2 Bn\$**  
 bought by
- #3 **4.3 Bn\$**  
 bought by

Source: BioCentury (July 2017)